ArticleBreast cancer research : BCR2026
Associations of oral contraceptives with expression of CD44, CD24, and ALDH1A1 stem cell markers in women with benign breast biopsies.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWe investigated the association between oral contraceptives (OCs) and CD44, CD24, and ALDH1A1 stem cell (SC) markers' expression in benign breast tissue.
methodsWe included 731 cancer-free women with biopsy-confirmed benign breast disease (BBD) within the Nurses' Health Study II. Information on OC use was collected in 1989 and updated biennially. Immunohistochemistry (IHC) was performed on tissue microarrays constructed from histologically normal breast tissue cores. For each core, the IHC expression was assessed with semi-automated software as the % of positively stained cells for each marker. Generalized linear regression was used to examine the associations of OCs (use status, total duration, age at first and last use, use before first pregnancy, and time since last use) with each marker's log-transformed expression (within stroma and epithelium).
resultsIn multivariate analyses, OC use was positively associated with stromal CD44 expression (current vs. never β = 0.75, 95% Confidence Interval [CI] 0.11, 1.39, p-trend = 0.02). Age at first use was inversely associated with CD44 expression (in stroma: β= -0.04, 95% CI -0.08, -0.01; in epithelium β= -0.04, 95% CI -0.06, -0.02). Use before first pregnancy was positively associated with CD44 in epithelium (β = 0.43; 95% CI 0.13, 0.74). Total duration, age at last use, and time since last use were not associated with any of the SC markers.
conclusionsOur findings suggest a greater expression of CD44 in the breast stroma of current OC users and a reduced CD44 expression with a later age at first OC use, consistent with the reported associations of OCs with BCa risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.